Skip to main content
SpringerLink
Log in

Chronische lymphatische Leukämie/lymphoplasmozytoides Lymphom

  • Chapter
Kompendium Internistische Onkologie

  • 165 Accesses

Zusammenfassung

Die chronisch lymphatische Leukämie (CLL) ist ein leukämisch verlaufendes, lymphozytisches Non-Hodgkin-Lymphom der B-Zell-Reihe von niedrigem Malignitätsgrad.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Anaissie EJ, Kontoyiannis DP, O’Brien S et al (1998) Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 129, 559–566

    PubMed  CAS  Google Scholar 

  • Angelopoulou MA, Poziopoulos C., Boussiotis VA et al (1996) Fludarabine monophosphate in refractory B-chronic lymphocytic leukemia: maintenance may be significant to sustain response, Leuk Lymphoma 21, 321–324

    PubMed  CAS  Google Scholar 

  • Anger C, Fink R, Fleischer J (1975) Vergleichsuntersuchung zwischen Cytostasan (Bendamustin) und Cyclophosphamid bei der chronischen Lymphadenose, dem Plasmozytom, der Lymphogranulomatose und dem Bronchialkarzinom, Dtsch Gesundheitswesen 30:1280–1285

    Google Scholar 

  • Bartlett NL, Longo DL (1999) T-small lymphocyte disorders, Semin Hematol 36:164–170

    PubMed  CAS  Google Scholar 

  • Bergmann (2005) (eingereicht)

    Google Scholar 

  • Bellosillo B, Villamor N, Colomer D et al (1999) In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood 94:2836–2843

    PubMed  CAS  Google Scholar 

  • Binet JL, Auquier A, Dighiero G et al (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48:198–204

    Article  PubMed  CAS  Google Scholar 

  • Bosch F, Ferrer A, Lopez-Guillermo A et al (2001) Fludarabine with cyclophosphamide and mitoxantrone (FCM) in resistant or relapsed chronic lymphocytic leukaemia (CLL): final results of a phase II study. Blood 98:(Suppl. 1), abstr 2655

    Google Scholar 

  • Burger JA, Burger M, Kipps TJ (1999) Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 94:3658–3667

    PubMed  CAS  Google Scholar 

  • Byrd J, Murphy T, Howard R et al (2001a) Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19:2153–2164

    PubMed  CAS  Google Scholar 

  • Byrd J, Peterson B, Park K et al (2001b) Concurrent rituximab and fludarabine has a higher complete response rate than sequential treatment in untreated chronic lymphyocytic leukemia (CLL) patients results from CALGB 9712, Blood 98 (Suppl. 1), Abstr 3212

    Google Scholar 

  • Byrd JC, Grever MR (2001) Finding new therapies for patients with chronic lymphocytic leukemia. In: B. Cheson (ed.) Chronic lymphoid leukemias. New York, Marcel Dekker, Inc

    Google Scholar 

  • Caligaris-Cappio F, Hamblin TJ (1999) B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol 17:399–408

    PubMed  CAS  Google Scholar 

  • Cantwell M, Hua T, Pappas J, Kipps TJ (1997) Acquired CD40-ligand deficiency in chronic lymphocytic leukemia, Nat Med 3:984–989

    Article  PubMed  CAS  Google Scholar 

  • Cheson BD (1998) Therapy for previously untreated chronic lymphocytic leukemia: a reevaluation, Semin Hematol 35:14–21

    PubMed  CAS  Google Scholar 

  • Cheson BD, Frame JN, Vena D et al (1998) Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia. J Clin Oncol 16:2313–2320

    PubMed  CAS  Google Scholar 

  • Cheson BD, Bennett JM, Grever M et al (1996) National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990–4997

    PubMed  CAS  Google Scholar 

  • CLL trialists’ collaborative group (1999) Chemotherapeutic options in chronic lymphocytic leukemia. J Natl Cancer Inst 91:861–868

    Article  Google Scholar 

  • Cooperative group for the study of Immunoglobulin in chronic lymphocytic leukemia (1988) Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized controlled clinical trial. N Engl J Med 319:902–907

    Google Scholar 

  • Criel A, Michaux L, De Wolf-Peeters C (1999). The concept of typical and atypical chronic lymphocytic leukaemia. Leuk Lymphoma 33:33–45

    PubMed  CAS  Google Scholar 

  • Damle RN, Wasil T, Fais F et al (1999) Ig V genemutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia [see comments], Blood 94:1840–1847

    PubMed  CAS  Google Scholar 

  • Dearden CE, Matutes E, Hilditch BL et al (1999) Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine. Br J Haematol 106:515–519

    Article  PubMed  CAS  Google Scholar 

  • Diehl LF, Ketchum LH (1998) Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 25:80–97

    PubMed  CAS  Google Scholar 

  • DiGiuseppe JA, Borowitz MJ (1998) Clinical utility of flow cytometry in the chronic lymphoid leukemias. Semin Oncol 25(1):6–10

    PubMed  CAS  Google Scholar 

  • Döhner H, Stilgenbauer S, Benner A et al (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910–1916

    Article  PubMed  Google Scholar 

  • Döhner H, Ho AD, Thaler J et al (1993) Pentostatin in prolymphocytic leukemia: Phase II Trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group. J Natl Cancer Inst 85:658–662

    Article  PubMed  Google Scholar 

  • Dreger P, Michallet M, Schmitz N (2000) Stem-cell transplantation for chronic lymphocytic leukemia: the 1999 perspective. Ann Oncol 11:49–53

    Article  PubMed  Google Scholar 

  • Dyer MJ (1999) The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies. Semin Oncol 26:52–57

    PubMed  CAS  Google Scholar 

  • Flinn IW, Byrd JC, Morrison C et al (2000) Fludarabine and cyclophosphamide with filgastrim support in patients with previously untreated indolent lymphoid malignancies. Blood 96:71–75

    PubMed  CAS  Google Scholar 

  • French Cooperative Group on Chronic Lymphocytic Leukemia (1986) Effectiveness of “CHOP” regimes in advanced untreated chronic lymphocytic leukemia. Lancet I, 1346–1349

    Google Scholar 

  • French Cooperative Group on CLL, Johnson S, Smith AG et al (1996) Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicine, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukemia. Lancet 347:1432–1438

    PubMed  CAS  Google Scholar 

  • Frewin R, Turner D, Tighe M et al (1999) Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders. Br J Haematol 104:612–613

    Article  PubMed  CAS  Google Scholar 

  • George JN, Woolf JH, Raskob GE et al (1996) Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 88:3–40

    PubMed  CAS  Google Scholar 

  • Golomb HM, Catovsky D, Golde DW (1978) Hairy cell leukemia: a clinical review based on 71 cases. Ann Intern Med 89:677–683

    PubMed  CAS  Google Scholar 

  • Gribben JG (1999) Stem-cell transplantation for indolent lymphoma. Semin Hematol 36:18–25

    PubMed  CAS  Google Scholar 

  • Grillo-Lopez AJ, White CA, Varns C et al (1999) Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 26:66–73

    PubMed  CAS  Google Scholar 

  • Hallek M., Bergmann M, Emmerich B (2002) Chronische lymphatische Leukämie: aktualisierte Vorschläge zu Diagnostik und Therapie. Dtsch Ärztebl 99:A1294–1301

    Google Scholar 

  • Hallek M, Schmitt B, Wilhelm M et al (2001) Fludarabine plus cyclophosphamide for the treatment of chronic lymphocytic leukemia: Results of a phase II study (CLL2 protocol) of the German CLL Study Group (GCLLSG). Br J Haematol 114:342–348

    Article  PubMed  CAS  Google Scholar 

  • Hallek M, Kuhn-Hallek I, Emmerich B (1997) Prognostic factors in chronic lymphocytic leukemia. Leukemia 11, Suppl 2:4–13

    Google Scholar 

  • Hamblin T (2002) The nature and natural history of early-stage B-CLL. Hematology 193–197

    Google Scholar 

  • Hamblin TJ, Davis Z, Gardiner A (1999) Unmutated IgV(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia [see comments]. Blood 94:1848–1854

    PubMed  CAS  Google Scholar 

  • Harris NL, Jaffe ES, Diebold J et al (2000) The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol 13:193–207

    Article  PubMed  CAS  Google Scholar 

  • Heider M, Gauler T, Niederle N (1999) Efficacy and toxicity of bendamustine in patients with relapsed low grade non-Hodgkin’s lymphoma (NHL) (abstr. 447). Ann Oncol 10 (Suppl. 13), 124

    Google Scholar 

  • Huhn D, von Schilling C, Wilhelm M et al (2001) Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98:1326–1331

    Article  PubMed  CAS  Google Scholar 

  • Jaksic B, Brugatelli M, Krc I et al (1997) High dose chlorambucil versus Binet’s modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Cancer 79:2107–2114

    Article  PubMed  CAS  Google Scholar 

  • Juliusson G (1997) Complications in the treatment of CLL with purine analogues. Hematol Cell Ther 39 Suppl 1, S41–S44

    Article  PubMed  Google Scholar 

  • Juliusson G, Christiansen I, Hansen MM et al (1996) Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J Clin Oncol 14:2160–2166

    PubMed  CAS  Google Scholar 

  • Juliusson G, Gahrton G (1993) Cytogenetics in CLL and related disorders. Baillieres Clin Haematol 6:821–848

    Article  PubMed  CAS  Google Scholar 

  • Juliusson G, Oscier DG, Fitchett M et al (1990) Prognostic subgroups in B-cell chronic lymphatic leukemia defined by specific chromosomal abnormalities. N Engl J Med 323:720–724

    PubMed  CAS  Google Scholar 

  • Juliusson G, Liliemark J (1993) High complete remission rate of 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia. Response predicted by rapid decrease in blood lymphocyte count. J Clin Oncol 11:679–689

    PubMed  CAS  Google Scholar 

  • Kath R, Blumenstengel K, Fricke HJ, Hoffken K (2001). Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol 127:48–54

    Article  PubMed  CAS  Google Scholar 

  • Keating M (1999) Improving the complete remission rate in chronic lymphocytic leukemia. Hematology 262–269

    Google Scholar 

  • Keating MJ, Kantarjian H, O’Brien S et al (1991) Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 9:44–49

    PubMed  CAS  Google Scholar 

  • Keating MJ, Kantarjian H, Redman J et al (1989) Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 74:19–25

    PubMed  CAS  Google Scholar 

  • Keating MJ, O’Brien S, Lerner S et al (1998). Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92:1165–1171

    PubMed  CAS  Google Scholar 

  • Keating MJ, Hester JP, McCredie KB et al (1990) Long-term results of CAP therapy in chronic lymphocytic leukemia. Leuk Lymphoma 2:391–397

    Article  Google Scholar 

  • Kennedy B, Rawstron A, Carter C et al (2002) Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 99:2245–2247

    Article  PubMed  CAS  Google Scholar 

  • Khouri IF, Keating M, Korbling M et al (1998) Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies [see comments]. J Clin Oncol 16:2817–2824

    PubMed  CAS  Google Scholar 

  • Klein U, Tu Y, Stolovitzky GA et al (2001). Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 194:1625–1638

    Article  PubMed  CAS  Google Scholar 

  • Kunzmann V, Ruediger T, Hallek M et al (2001). Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment. Blood 98:1991–1992

    Article  PubMed  CAS  Google Scholar 

  • Lens D, De Schouwer, PJ, Hamoudi RA et al (1997) p53 abnormalities in B-cell prolymphocytic leukemia. Blood 89:2015–2023

    PubMed  CAS  Google Scholar 

  • Lens D, Matutes E, Catovsky D, Coignet LJ (2000). Frequent deletions at 11q23 and 13q14 in B cell prolymphocytic leukemia (B-PLL). Leukemia 14(3):427–430

    Article  PubMed  CAS  Google Scholar 

  • Leporrier M, Chevret S, Cazin B et al (2001) Randomized comparison of fludarabine, CAP, and CHOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 98:2319–2325

    Article  PubMed  CAS  Google Scholar 

  • Luo L, Lu FM, Hart S et al (1998) Ataxia-telangiectasia and T-cell leukemias: no evidence for somatic ATM mutation in sporadic T-ALL or for hypermethylation of the ATM-NPAT/E14 bidirectional promoter in T-PLL [published erratum appears in Cancer Res 1998 Aug 1;58(15):3488]. Cancer Res 58:2293–2297

    PubMed  CAS  Google Scholar 

  • Manero GG, O’Brien S, Cortes J et al (2001) Update of results of the combination of fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL), Blood 98 (Suppl. 1), abstr 2650

    Google Scholar 

  • Matutes E, Brito-Babapulle V, Swansburg J et al (1991) Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 78:3269–3274

    PubMed  CAS  Google Scholar 

  • Mauro FR, Foa R, Giannarelli D et al (1999) Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood 94:448–454

    PubMed  CAS  Google Scholar 

  • Meinhardt G, Wendtner CM, Hallek M (1999) Molecular pathogenesis in chronic lymphocytic leukemia: factors and signaling pathways regulating cell growth and survival. J Mol Med 77:282–293

    Article  PubMed  CAS  Google Scholar 

  • Meloni G, Proia A, Mauro F et al (2000) Unmanipulated peripheral blood stem cell autograft in chronic lymphocytic leukemia: clinical findings and biological monitoring. Haematologica 85:952–960

    PubMed  CAS  Google Scholar 

  • Montserrat E, Lopez-Lorenzo JL, Manso F et al (1996) Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia: the Spanish Group experience. Leuk Lymphoma 21:467–472

    Article  PubMed  CAS  Google Scholar 

  • Montserrat E, Vinolas N, Reverter JC, Rozman C (1988) Natural history of chronic lymphocytic leukemia: on the progression and prognosis of early clinical stages. Nouv Rev Fr Hematol 30:359–361

    PubMed  CAS  Google Scholar 

  • Montserrat E, Alcala A, Parody R et al (1985) Treatment of chronic lymphocytic leukemia in advanced stages: A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamid, vincristine and prednisone. Cancer 56:2369–2375

    Article  PubMed  CAS  Google Scholar 

  • Moreau EJ, Matutes E, A’Hern RP et al (1997) Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol 108:378–382

    PubMed  CAS  Google Scholar 

  • Morrison VA (1998) The infectious complications of chronic lymphocytic leukemia. Semin Oncol 25:98–106

    PubMed  CAS  Google Scholar 

  • Nguyen DT, Amess JA, Doughty H et al (1999) IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin’s lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur J Haematol 62:76–82

    PubMed  CAS  Google Scholar 

  • O’Brien S, Kantarijan H, Thomas D et al (2001a) Rituximab dose-escalation trial in chronic lymphocytic leukaemia. J Clin Oncol 19:2165–2170

    PubMed  Google Scholar 

  • O’Brien S, Kantarjian H, Cortes J et al. (2001b) Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 19:1414–1420

    PubMed  Google Scholar 

  • Österborg A, Dyer MJ, Bunjes D et al (1997) Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leucemia. European study group of CAMPATH-1H treatment in chronic lymphocytic leukemia. J Clin Oncol 15:1567–1574

    PubMed  Google Scholar 

  • Osterborg A, Fassas AS, Anagnostopoulos A et al (1996) Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol 93:151–153

    Article  PubMed  CAS  Google Scholar 

  • Pawson R, Dyer MJ, Barge et al (1997) Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 15:2667–2672

    PubMed  CAS  Google Scholar 

  • Piro LD, Carrera CJ, Beutler E, Carson DA (1988) Chlorodeoxyadenosine. An effective new agent for the treatment of chronic lymphocytic leukemia. Blood 72:1069–1073

    PubMed  CAS  Google Scholar 

  • Rai KR, Peterson BL, Appelbaum FR et al (2000) Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343:1750–1757

    Article  PubMed  CAS  Google Scholar 

  • Rai KR, Rabinowe SN (1993) Chronic lymphocytic leukemia. In: Holland IF, Frei E III, Bart RC et al (eds) Cancer Medicine, vol II, 3rd edn. Lea 1988

    Google Scholar 

  • Reed JC (1998) Molecular biology of chronic lymphocytic leukemia. Semin Oncol 25:11–18

    PubMed  CAS  Google Scholar 

  • Robak T, Blonski JZ, Kasznicki M et al (2000) Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 96:2723–2729

    PubMed  CAS  Google Scholar 

  • Rosenwald A, Alizadeh AA, Widhopf G et al (2001) Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 194:1639–1647

    Article  PubMed  CAS  Google Scholar 

  • Rozman C, Montserrat E (1995) Chronic lymphocytic leukemia. N Engl J Med 333:1052–1057

    Article  PubMed  CAS  Google Scholar 

  • Rummel MJ, Kafer G, Pfreundschuh M et al (1999) Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: a German multicenter phase II study. Ann Oncol 10:183–188

    Article  PubMed  CAS  Google Scholar 

  • Saven A, Lemon RH, Kosty M et al (1995) 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 13:570–574

    PubMed  CAS  Google Scholar 

  • Schulz H, Klein S, Rehwald U et al (2001) Phase II-study of rituximab in combination with fludarabine in patients with chronic lymphocytic leukemia (CLL), Blood 98 (Suppl. 1), Abstr 1534

    Google Scholar 

  • Shvidel L, Shtalrid M, Bassous L et al (1999) B-cell prolymphocytic leukemia: a survey of 35 patients emphasizing heterogeneity, prognostic factors and evidence for a group with an indolent course. Leuk Lymphoma 33:169–179

    PubMed  CAS  Google Scholar 

  • Sorensen JM, Vena DA, Fallavollita A et al (1997) Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report. J Clin Oncol 15, 458–465

    PubMed  CAS  Google Scholar 

  • Stilgenbauer S, Schaffner C, Litterst A et al (1997) Biallelicmutations in the ATM gene in T-prolymphocytic leukemia. Nat Med 3:1155–1159

    Article  PubMed  CAS  Google Scholar 

  • Tallman MS, Peterson LC, Hakimian D et al (1999) Treatment of hairy-cell leukemia: current views. Semin Hematol 36:155–163

    PubMed  CAS  Google Scholar 

  • Tang SC, Hewitt K, Reis MD, Berinstein NL (1996) Immunosuppressive toxicity of CAMPATH1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma. Leuk Lymphoma 24:93–101

    Article  PubMed  CAS  Google Scholar 

  • Toze CL, Shepherd JD, Connors JM et al (2000) Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia. Bone Marrow Transplant 25:605–612

    Article  PubMed  CAS  Google Scholar 

  • Waselenko JK, Flynn JM, Byrd JC (1999) Stem-cell transplantation in chronic lymphocytic leukemia: The time for designing randomized studies has arrived. Semin Oncol 26:48–61

    PubMed  CAS  Google Scholar 

  • Wendtner C-M, Kofler D, Theiss HD et al (2002) Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors. Blood 100:1655–1661

    PubMed  CAS  Google Scholar 

  • Wierda W, OłBrien S, Albitar M et al (2001) Combined fludarabine, cyclophosphamide and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia. Blood 98 (Suppl. 1), abstr 3210

    Google Scholar 

  • Wierda WG, Cantwell MJ, Woods SJ et al (2000) CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 96:2917–2924

    PubMed  CAS  Google Scholar 

  • Wilhelm M, Tony HP, Rueckle-Lanz H, Wilms K (1997) First-line therapy of advanced chronic lymphatic leukemia. Leukemia 11 Suppl 2, S14–18

    PubMed  Google Scholar 

  • Winkler U, Jensen M, Manzke O et al (1999) Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94:2217–2224

    PubMed  CAS  Google Scholar 

  • Yuille MA, Coignet LJ, Abraham SM et al (1998) ATM is usually rearranged in T-cell prolymphocytic leukaemia [published erratum appears in Oncogene 1998 Jun 4;16(22):2955], Oncogene 16:789–796

    Article  PubMed  CAS  Google Scholar 

  • Zaja F, Rogato A, Russo D et al (1997) Combined therapy with fludarabine and cyclophosphamide in relapsed/resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin’s lymphomas [letter]. Eur J Haematol 59:327–328

    Article  PubMed  CAS  Google Scholar 

  • Zimmer-Molsberger B, Knauf W, Thiel E (1997) Mycophenolate mofetil for severe autoimmune haemolytic anemia [letter], Lancet 350:1003–1004

    Article  PubMed  CAS  Google Scholar 

  • Zwiebel JA, Cheson BD (1998) Chronic lymphocytic leukemia: staging and prognostic factors. Semin Oncol 25:42–59

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. M. Hallek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Emmerich
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Schwerpunkt Hämatologie/Onkologie, Martin-Luther-Universität Halle-Wittenberg, Ernst-Grube-Straße 40, 06120, Halle/Saale

    Hans-Joachim Schmoll (Direktor der Klinik und Poliklinik für Innere Medizin IV) (Direktor der Klinik und Poliklinik für Innere Medizin IV)

  2. Onkologie-Hämatologie-Gastroenterologie-Hepatologie-Infektiologie, Klinikum der Friedrich-Schiller-Universität Jena, Erlanger Allee 101, 07740, Jena

    Klaus Höffken (Direktor der Klinik und Poliklinik für Innere Medizin II) (Direktor der Klinik und Poliklinik für Innere Medizin II)

  3. Schwerpunkt Onkologie und Hämatologie, Universitätsmedizin Berlin, Charité-Campus Mitte Schumannstraße 20/21, 10117, Berlin

    Kurt Possinger (Direktor der Medizinischen Klinik II) (Direktor der Medizinischen Klinik II)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Hallek, M., Emmerich, B. (2006). Chronische lymphatische Leukämie/lymphoplasmozytoides Lymphom. In: Schmoll, HJ., Höffken, K., Possinger, K. (eds) Kompendium Internistische Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-31303-6_173

Download citation

  • DOI: https://doi.org/10.1007/3-540-31303-6_173

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-20657-6

  • Online ISBN: 978-3-540-31303-8

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation